Acne severity tools vary between clinical trials because there is no universally accepted gold standard for measuring acne severity. Instead, more than 25 different grading systems exist, and researchers use them inconsistently across studies. This fundamental lack of standardization means that when one clinical trial reports a 50% improvement in acne severity, and another reports 60% improvement, the numbers may not be directly comparable—they could be measuring improvement using entirely different scales.
For example, one trial might measure only inflammatory lesions using the Global Acne Grading System (GAGS), while another measures total lesion count with the Investigator Global Assessment (IGA), leading to incomparable results despite testing similar treatments. The problem is so widespread that the FDA’s Dermatologic and Ophthalmic Drugs Advisory Committee formally recognized it in November 2002, noting that acne’s complex nature makes it inherently difficult to standardize severity assessment. In recent research examining 18 clinical trials, scientists found 25 different ways of reporting lesion count changes, 25 ways of reporting grade changes, and 14 different acne grading systems being used to measure treatment response. This article explores why these tools vary so dramatically, how subjectivity and methodology create inconsistencies, and what researchers are doing to address the problem.
Table of Contents
- How Many Different Acne Grading Systems Actually Exist?
- Why the FDA Recognized Standardization as a Critical Problem
- The Human Factor—Subjectivity and Individual Interpretation
- Comparing the Major Assessment Tools and Their Trade-offs
- Lesion Counting Versus Global Grading—The Accuracy-Practicality Tradeoff
- What Gets Missed When Current Systems Focus Only on Lesion Count
- The Future—Moving Toward Objective, Standardized Measurement
- Conclusion
How Many Different Acne Grading Systems Actually Exist?
The sheer proliferation of acne grading scales is staggering. More than 25 different systems are currently in use or have been validated in published research, with no single tool achieving universal acceptance in clinical practice or research. Some scales focus exclusively on inflammatory lesions, others count total lesions, while still others incorporate evaluations of scarring, hyperpigmentation, and even psychological impact. This diversity sounds like it should offer flexibility, but instead it creates a Tower of Babel in dermatological research.
The most commonly used scales—including GAGS (Global Acne Grading System), iga (Investigator Global Assessment), and the Spanish Acne Severity Scale (EGAE)—each have their own methodologies and interpretation guidelines. The EGAE, validated in 2013, uses a visual photonumeric scale and demonstrates high interobserver reliability. Yet the fact that researchers developed this newer system suggests the older ones had limitations that prompted innovation. When researchers can choose from dozens of assessment tools, they inevitably choose different ones, making it nearly impossible to compare results across trials.
Why the FDA Recognized Standardization as a Critical Problem
In 2002, the FDA’s advisory committee made an important acknowledgment: acne’s “pleomorphic nature”—its tendency to present differently across different people—makes it inherently challenging to create one universal severity measure. This wasn’t just a casual observation; it was an official recognition that the regulatory body overseeing drug approvals understood that current assessment methods had built-in limitations. The committee’s statement essentially admitted that no single grading system could capture the full complexity of acne severity in a way that satisfied all clinical and research needs.
This recognition had real consequences. Because the FDA couldn’t demand a single gold standard, dermatologists and researchers adapted by accepting multiple validated scales, each appropriate for different contexts. However, this flexibility came at a cost: the absence of an internationally accepted measure of acne severity has impeded quality clinical research and adoption of best practices. When pharmaceutical companies submit new acne treatments for FDA approval, they can choose their own preferred assessment tool, leading to another layer of inconsistency in the data that regulators review.
The Human Factor—Subjectivity and Individual Interpretation
At the heart of acne severity variation is a simple truth: clinician interpretation differs based on experience, visual acuity, lighting conditions, and even the patient‘s skin type. Two dermatologists looking at the same patient’s back may assign different severity grades because they assess lesions through slightly different lenses—literally and figuratively. Research has shown surprising variability of responses even among experienced dermatologists, with significant disagreement about lesion counts and severity classifications. The terminology itself introduces inconsistency.
The term “severe acne” means different things to different clinicians. Does it mean 40 inflammatory lesions? 100 total lesions? Any nodular acne? Any scarring present? Without precise definitions embedded in the assessment tool, clinicians rely on personal experience and judgment. Additionally, most current grading systems fail to evaluate critical aspects of acne beyond surface lesions—including post-inflammatory hyperpigmentation, scarring risk, and psychological impact on quality of life and self-esteem. A patient with 15 inflammatory lesions but significant scarring and depression might be categorized differently depending on whether the scale even attempts to capture those dimensions.
Comparing the Major Assessment Tools and Their Trade-offs
The most widely used tools each reflect different philosophies about what matters in measuring acne severity. The Global Acne Grading System (GAGS) is detailed and comprehensive but requires careful training to apply correctly, making it complex for routine use. The Investigator Global Assessment (IGA), FDA-approved since 2005, has become the industry standard for clinical trials because it’s faster and more practical—but this speed comes at the cost of increased subjectivity. A clinician using IGA might rate acne based on overall appearance without precise lesion counts, which two different dermatologists might interpret differently.
The Spanish Acne Severity Scale (EGAE) represents an attempt to improve upon these earlier tools by combining a visual photonumeric scale with clearer severity categories. Studies show this system has high interobserver reliability and good sensitivity to treatment effects, suggesting it addresses some of the problems inherent in more subjective systems. However, EGAE is less commonly used in international trials than GAGS or IGA, so choosing it as your trial’s assessment tool means your results will be less directly comparable to the majority of existing studies. Researchers face a genuine dilemma: use an older, more widely recognized scale that may have known limitations, or use a newer, potentially superior scale that makes cross-trial comparisons harder.
Lesion Counting Versus Global Grading—The Accuracy-Practicality Tradeoff
Lesion counting is the most objective way to measure acne severity: a researcher or AI system literally counts every visible lesion and records the number. This is the reference standard for accuracy, and when done carefully, it produces reproducible results that don’t depend on subjective interpretation. However, lesion counting is extraordinarily time-consuming and impractical for routine clinical practice. A thorough lesion count on a patient with extensive back acne might take 10–15 minutes per assessment, which means a researcher performing multiple patient assessments daily faces enormous time demands.
In contrast, global severity grading allows a clinician to assess acne in seconds by assigning an overall grade (mild, moderate, severe) based on visual impression. This efficiency makes it the preferred method in busy office settings and many clinical trials. The trade-off is obvious: global grading is fast but subjective, while lesion counting is accurate but slow. Most clinical trials try to find middle ground by using a hybrid approach—counting lesions in specific body areas (like the face) while using global assessment for other areas—but this compromise introduces yet another source of variation across trials.
What Gets Missed When Current Systems Focus Only on Lesion Count
Most acne severity scales were designed with a narrow focus: counting or grading lesions. This leaves enormous gaps in what actually matters to patients and dermatologists assessing treatment success. Post-inflammatory hyperpigmentation (darkening of skin where lesions healed) is extremely common in darker skin types, can persist for months, and significantly impacts quality of life, yet many grading systems don’t measure it at all. Similarly, early scarring or risk of scarring is not systematically captured by scales designed purely for lesion counting.
Psychological impact represents another major unmeasured dimension. A teenager with 20 inflammatory lesions but experiencing severe depression and social withdrawal due to their acne may benefit more from treatment than another teen with 30 lesions but minimal psychological distress. Yet most severity tools would rank the second case as “worse” simply because the lesion count is higher. This gap between what severity scales measure and what actually matters to patients creates a fundamental mismatch in clinical research, where trials report improvements in lesion count while patients report improvements in quality of life that may or may not correlate.
The Future—Moving Toward Objective, Standardized Measurement
Emerging research is exploring artificial intelligence and machine learning as potential solutions to the standardization problem. These tools could develop acne grading scales that are simultaneously objective, accurate, comprehensive, and easy to use across different clinical settings and skin types. AI systems trained on thousands of high-quality images of acne at different severity levels could potentially assess lesions, hyperpigmentation, scarring potential, and other factors automatically, reducing human subjectivity while improving consistency.
A 2025 study published in JMIR Dermatology examined how machine learning could create standardized, reproducible acne assessment tools. While this technology is still emerging, the principle is clear: moving away from human visual judgment toward standardized computational assessment could finally solve the comparability problem that has plagued acne research for decades. However, these tools will need to be carefully validated across different skin types and populations before they can become the new gold standard, and the adoption process will likely be slow given the entrenched use of existing scales.
Conclusion
Acne severity tools vary between clinical trials because the field has never adopted a single gold standard, instead relying on more than 25 different grading systems, each with its own methodology, strengths, and limitations. This fragmentation arose partly from acne’s inherent complexity, which the FDA acknowledged in 2002 as a genuine challenge to standardization, and partly from practical trade-offs between accuracy and ease of use. The result is that clinical trial results often measure different things using different scales, making it difficult to compare which treatments are truly most effective.
Understanding this variation matters both for patients evaluating their acne treatment options and for dermatologists interpreting clinical evidence. When reading a study showing improvement in acne severity, it’s worth asking which grading system was used, whether lesions were counted or subjectively assessed, and what dimensions of acne—like scarring or quality of life—were actually measured. As machine learning and AI-based assessment tools continue to develop, the field may finally move toward the universal, reproducible severity measurement that has eluded dermatology for decades, making future clinical trials more directly comparable and patients better informed.
